Pharmaceuticals, Biotechnology & Life Sciences

AbbVie’s musculoskeletal oncology focus, strong cash flow and strategic M&A plans are driving bullish analyst sentiment and higher price targets despite looming patent cliffs.

Explore Sartorius AG’s stock volatility, TecDAX trends, and ten‑year growth—learn how its precision biotech focus drives long‑term investor value.

Explore why Bayer’s Q3 earnings are met with muted market reaction—discover the company’s strategic shift to China and how its dual pharma‑agri portfolio aims to thrive amid global uncertainties.

Merck KGaA secures 16 MW of renewable power in South Korea with a 20‑year PPA to hit 80 % renewable electricity by 2030, cutting CO₂ and boosting investor confidence.

Pfizer’s Q3 2025 earnings show a 3.8 % revenue dip but beat EPS estimates, thanks to cost discipline and a growing specialty drug focus, while the Metsera bid and tightening drug‑pricing regulations pose key risks and opportunities for investors.

Novo Nordisk’s upgraded offer for Metsera could diversify its obesity drugs and edge out Pfizer, but success hinges on regulatory approval and integration – investors weigh short‑term dilution against long‑term upside.

Johnson & Johnson’s latest fiscal results show strong growth and a focus on pulsed‑field ablation innovation, trade‑risk strategy, and quality‑driven cost control—insightful data for investors and healthcare analysts.

Discover Daiichi Sankyo’s Q2 2026 earnings insights—financial highlights, growth drivers, pipeline focus, and strategic plans that shape investor outlook.

Regeneron’s upcoming investor conferences reveal new Dupixent data, expanded approvals, and strategic plans—key insights for analysts and healthcare investors.

Read how AstraZeneca’s shareholder‑approved NYSE direct listing will boost capital for oncology and cardiovascular R&D, improve market visibility, and speed patient access to new therapies.